Alpha-v Integrins as Therapeutic Targets in Oncology

Integrins are heterodimeric cell adhesion receptors that mediate intercellular communication through cell-extracellular matrix interactions and cell-cell interactions. Integrins have been demonstrated to play a direct role in cancer progression, specifically in tumor cell survival, tumor angiogenesis, and metastasis. Therefore, agents targeted against integrin function have potential as effective anticancer therapies. Numerous anti-integrin agents, including monoclonal antibodies and small-molecule inhibitors, are in clinical development for the treatment of solid and hematologic tumors. This review focuses on the role of αv integrins in cancer progression, the current status of integrin-targeted agents in development, and strategies for the clinical development of anti-integrin therapies.

[1]  M. Allende-Vigo.  The use of biochemical markers of bone turnover in osteoporosis. , 2007, Puerto Rico health sciences journal.

[2]  M. Schwaiger,et al.  PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  M. Chamberlain.  Treatment options for glioblastoma. , 2006, Neurosurgical focus.

[4]  F. Spinella,et al.  Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma , 2006, Molecular Cancer Therapeutics.

[5]  W. Cai,et al.  Multimodality tumor imaging targeting integrin alphavbeta3. , 2005, BioTechniques.

[6]  M. Schwaiger,et al.  Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  L. Nabors,et al.  Treatment of adults with recurrent malignant glioma , 2005, Expert review of neurotherapeutics.

[8]  J. Sosman,et al.  A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, {+/-} dacarbazine (DTIC) in patients with metastatic melanoma (MM) , 2005 .

[9]  A. Tolcher,et al.  Pharmacokinetics (PK) and pharmacodynamics (PD) of E7820-an oral sulfonamide with novel, alpha-2 integrin mediated antiangiogenic properties: Results of a phase I study , 2005 .

[10]  J. Qin,et al.  VEGF-integrin interplay controls tumor growth and vascularization. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  F. Carreiras,et al.  Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves αv integrins and the participation of MMP2 , 2005, International journal of cancer.

[12]  M. Schmitt,et al.  ADAM15 decreases integrin αvβ3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion , 2005 .

[13]  Horst Kessler,et al.  Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD , 2005, PLoS medicine.

[14]  Napoleone Ferrara,et al.  Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. , 2005, Cancer research.

[15]  E. Eisenhauer.  Special Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism , 2005 .

[16]  M. Schmitt,et al.  ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion. , 2005, The international journal of biochemistry & cell biology.

[17]  M. Schwaiger,et al.  Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  R. D'Amato,et al.  Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. , 2005, Cancer cell.

[19]  Weibo Cai,et al.  Multimodality tumor imaging targeting integrin α v β 3 , 2005 .

[20]  F. Giancotti,et al.  Integrin β4 signaling promotes tumor angiogenesis , 2004 .

[21]  K. Pienta,et al.  Apoptosis of circulating tumor cells in prostate cancer patients , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[22]  Wenjun Guo,et al.  Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.

[23]  S. Goodman,et al.  Immunohistochemical screening for β6‐integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up‐regulation in pancreatic ductal adenocarcinomas in vivo and in vitro , 2004 .

[24]  A. Tolcher,et al.  166 A phase I dose-escalation study of anti-a5β1 integrin monoclonal antibody (M200) in patients with refractory solid tumors , 2004 .

[25]  R. Eckert,et al.  In Vitro Internalization, Intracellular Transport, and Clearance of an Anti-CD11a Antibody (Raptiva) by Human T-Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[26]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[27]  Amy P N Skubitz,et al.  Differential gene expression in ovarian carcinoma: identification of potential biomarkers. , 2004, The American journal of pathology.

[28]  G. Jayson,et al.  Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to αv integrins, in patients with solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  E. Eisenhauer,et al.  Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. , 2004, Journal of the National Cancer Institute.

[30]  M. Trikha,et al.  CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo , 2004, International journal of cancer.

[31]  Helen X. Chen.  Expanding the clinical development of bevacizumab. , 2004, The oncologist.

[32]  L. Mortelmans,et al.  Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[33]  Pauline Chu,et al.  A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. , 2004, International journal of radiation oncology, biology, physics.

[34]  H. Oettle,et al.  Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. , 2004, Oral oncology.

[35]  Rex Moats,et al.  18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. , 2004, Nuclear medicine and biology.

[36]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[37]  D. Taverna,et al.  Increased primary tumor growth in mice null for β3- or β3/β5-integrins or selectins , 2004 .

[38]  M. Ratain,et al.  Development of Target-Based Antineoplastic Agents , 2000, Investigational New Drugs.

[39]  F. Giancotti,et al.  Integrin beta4 signaling promotes tumor angiogenesis. , 2004, Cancer cell.

[40]  D. Taverna,et al.  Increased primary tumor growth in mice null for beta3- or beta3/beta5-integrins or selectins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Goodman,et al.  Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. , 2004, Histopathology.

[42]  M. Trikha,et al.  Inhibition of αvβ3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases , 2004, Clinical & Experimental Metastasis.

[43]  B. Felding-Habermann,et al.  Integrin adhesion receptors in tumor metastasis , 2004, Clinical & Experimental Metastasis.

[44]  E. Casper,et al.  Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas , 2004, Investigational New Drugs.

[45]  L. Ellis.  Antiangiogenic therapy at a crossroads: clinical trial results and future directions. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Folkman,et al.  Fundamental concepts of the angiogenic process. , 2003, Current molecular medicine.

[47]  F. Cavalli,et al.  A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. , 2003, Blood.

[48]  L. Knight,et al.  Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3). , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[49]  B. Davidson,et al.  αV- and β1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients , 2003 .

[50]  Martin A Lodge,et al.  Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  D. Schuppan,et al.  Integrin‐mediated control of cell growth , 2003, Hepatology.

[52]  Jinyuan Zhou,et al.  Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI , 2003, Nature Medicine.

[53]  M. Dewhirst,et al.  A clinical model of dermal wound angiogenesis , 2003, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[54]  B Landuyt,et al.  Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 , 2003, British Journal of Cancer.

[55]  G. Tucker.  Alpha v integrin inhibitors and cancer therapy. , 2003, Current opinion in investigational drugs.

[56]  R. Jain,et al.  Role of bone marrow-derived cells in tumor angiogenesis and treatment. , 2003, Cancer cell.

[57]  J. Verweij,et al.  Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours , 2003 .

[58]  F. Cavalli,et al.  Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  L. Ellis,et al.  Promises and pitfalls of anti-angiogenic therapy in clinical trials. , 2003, Trends in molecular medicine.

[60]  M. Dowsett,et al.  Current Perspectives on HER2 Testing: A Review of National Testing Guidelines , 2003, Modern Pathology.

[61]  Bruce Klitzman,et al.  Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  L. Knight,et al.  Radiopharmaceuticals for targeting the angiogenesis marker αvβ3 , 2003 .

[63]  B. Davidson,et al.  AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. , 2003, Gynecologic Oncology.

[64]  M. Trikha,et al.  Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. , 2003, Clinical & experimental metastasis.

[65]  Matthias Glaser,et al.  Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. , 2003, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[66]  A. Reynolds,et al.  Nanoparticle-mediated gene delivery to tumour neovasculature. , 2003, Trends in Molecular Medicine.

[67]  J. Verweij,et al.  Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. , 2003, European journal of cancer.

[68]  Jeffrey W. Smith.  Cilengitide Merck. , 2003, Current opinion in investigational drugs.

[69]  J. Folkman.  Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[70]  S. Mousa,et al.  The αv integrin antagonists as novel anticancer agents: an update , 2002 .

[71]  P. Price,et al.  PET for in vivo pharmacokinetic and pharmacodynamic measurements. , 2002, European journal of cancer.

[72]  R. Wilder,et al.  Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases , 2002, Annals of the rheumatic diseases.

[73]  T. Owa,et al.  Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. , 2002, Cancer research.

[74]  Roy Bicknell,et al.  The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. , 2002, Cancer research.

[75]  P. Speight,et al.  Binding of TGF-β1 latency-associated peptide (LAP) to αvβ6 integrin modulates behaviour of squamous carcinoma cells , 2002, British Journal of Cancer.

[76]  Jamal Zweit,et al.  Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. , 2002, Journal of the National Cancer Institute.

[77]  David A. Cheresh,et al.  Get a ligand, get a life: integrins, signaling and cell survival , 2002, Journal of Cell Science.

[78]  R. Hynes.  A reevaluation of integrins as regulators of angiogenesis , 2002, Nature Medicine.

[79]  Kathleen R. Lamborn,et al.  Cilengitide Targeting of αvβ3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts , 2002 .

[80]  G. Tucker.  Inhibitors of integrins. , 2002, Current opinion in pharmacology.

[81]  Tanja Fehm,et al.  Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[82]  G. Sledge.  Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. , 2002, Seminars in oncology.

[83]  M. Trikha,et al.  Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. , 2002, Cancer research.

[84]  N. Thacker,et al.  Breath‐hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first‐pass leakage profile model , 2002, NMR in biomedicine.

[85]  Yuji Nakamoto,et al.  Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[86]  B. Leyland-Jones.  Trastuzumab: hopes and realities. , 2002, The Lancet. Oncology.

[87]  D. Stupack,et al.  Integrin-mediated death: An explanation of the integrin-knockout phenotype? , 2002, Nature Medicine.

[88]  C. Giachelli,et al.  The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. , 2002, Trends in cardiovascular medicine.

[89]  David A. Cheresh,et al.  Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.

[90]  S. Brüsselbach,et al.  A NEW COLLOIDAL LIPIDIC SYSTEM FOR GENE THERAPY , 2002, Journal of liposome research.

[91]  S. Mousa,et al.  The alpha v integrin antagonists as novel anticancer agents: an update. , 2002, Expert opinion on investigational drugs.

[92]  D. Taverna,et al.  Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. , 2002, Nature medicine.

[93]  G. Sledge,et al.  Angiogenesis and antiangiogenic therapy. , 2002, Current problems in cancer.

[94]  D. Taverna,et al.  The diverse roles of integrins and their ligands in angiogenesis. , 2002, Cold Spring Harbor symposia on quantitative biology.

[95]  K. Lamborn,et al.  Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. , 2002, Cancer research.

[96]  B. Leyland-Jones.  Maximizing the response to Herceptin® therapy through optimal use and patient selection , 2001, Anti-cancer drugs.

[97]  P. Richardson,et al.  Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications , 2001, Leukemia.

[98]  B. Eliceiri.  This Review is part of a thematic series on Integrins, which includes the following articles: Integrins and the Myocardium Functional Consequences of Integrin Gene Mutations in Mice Integrins in Vascular Development Integrin and Growth Factor Receptor Crosstalk , 2001 .

[99]  J. Foidart,et al.  The Role of Integrins in Human Embryo Implantation , 2001, Fetal Diagnosis and Therapy.

[100]  W. Westlin.  Integrins as targets of angiogenesis inhibition. , 2001, Cancer journal.

[101]  A R Padhani,et al.  Challenges for imaging angiogenesis. , 2001, The British journal of radiology.

[102]  L. Ellis,et al.  Overview of angiogenesis: Biologic implications for antiangiogenic therapy. , 2001, Seminars in oncology.

[103]  R. Benjamin,et al.  Pilot study of vitaxin—an angiogenesis inhibitor—in patients with advanced leiomyosarcomas , 2001, Cancer.

[104]  Arnoud Sonnenberg,et al.  Function and interactions of integrins , 2001, Cell and Tissue Research.

[105]  Cheson Bd,et al.  Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. , 2001 .

[106]  A R Padhani,et al.  Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. , 2001, Clinical radiology.

[107]  H X Chen,et al.  Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. , 2001, Oncology.

[108]  J. Blondal,et al.  Defining a Test for HER-2/neu Evaluation in Breast Cancer in the Diagnostic Setting , 2001, Modern Pathology.

[109]  G. Adams,et al.  High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.

[110]  A. Goldhirsch,et al.  Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. , 2001, Blood.

[111]  D. Hayes,et al.  When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  J. Posey,et al.  A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. , 2001, Cancer biotherapy & radiopharmaceuticals.

[113]  Tsongalis Gj,et al.  HER2: the neu prognostic marker for breast cancer. , 2001 .

[114]  S. Mousa,et al.  Alpha(v)beta(3) integrin in angiogenesis and restenosis. , 2001, Drug news & perspectives.

[115]  J. Breed,et al.  Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  Hiroyuki Shimada,et al.  Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist , 2001, Neurosurgery.

[117]  G. Tsongalis,et al.  HER2: The Neu Prognostic Marker for Breast Cancer , 2001, Critical reviews in clinical laboratory sciences.

[118]  R Simon,et al.  Clinical trial designs for cytostatic agents: are new approaches needed? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  K. Mikecz.  Vitaxin applied molecular evolution. , 2000, Current opinion in investigational drugs.

[120]  F. Mitjans,et al.  In vivo therapy of malignant melanoma by means of antagonists of αv integrins , 2000 .

[121]  T. N. Campbell,et al.  Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[122]  Li Zhang,et al.  Ligand Binding to Integrins* , 2000, The Journal of Biological Chemistry.

[123]  D. Cheresh,et al.  Role of alpha v integrins during angiogenesis. , 2000, Cancer journal.

[124]  R. D'Amato,et al.  Genetic heterogeneity of angiogenesis in mice , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[125]  K. Lamborn,et al.  Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. , 2000, Cancer biotherapy & radiopharmaceuticals.

[126]  B. Neustadt,et al.  Targeting Integrins αvβ3 and αvβ5 for Bloking Tumor-Induced Angiogenesis , 2000 .

[127]  J. Cherrington,et al.  New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. , 2000, Advances in cancer research.

[128]  F. Mitjans,et al.  In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. , 2000, International journal of cancer.

[129]  B. Neustadt,et al.  Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis. , 2000, Advances in experimental medicine and biology.

[130]  S. Kim,et al.  Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. , 2000, The Journal of biological chemistry.

[131]  R. Eastell,et al.  The Use of Biochemical Markers of Bone Turnover in Osteoporosis , 2000, Osteoporosis International.

[132]  G. Mizejewski,et al.  Role of integrins in cancer: survey of expression patterns. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[133]  C. Dinney,et al.  Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[134]  Michal Neeman,et al.  In Vivo Prediction of Vascular Susceptibility to Vascular Endothelial Growth Factor Withdrawal Magnetic Resonance Imaging of C6 Rat Glioma in Nude Mice , 1999 .

[135]  J L Evelhoch,et al.  Key factors in the acquisition of contrast kinetic data for oncology , 1999, Journal of magnetic resonance imaging : JMRI.

[136]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[137]  F. Mitjans,et al.  Integrin αVβ3 Promotes M21 Melanoma Growth in Human Skin by Regulating Tumor Cell Survival , 1999 .

[138]  E. Eisenhauer,et al.  Multinomial phase II cancer trials incorporating response and early progression. , 1999, Journal of biopharmaceutical statistics.

[139]  D. Cheresh,et al.  The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.

[140]  D. Cheresh,et al.  Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[141]  N. Kaminski,et al.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. , 1999, Cell.

[142]  G. Curley,et al.  Integrin antagonists , 1999, Cellular and Molecular Life Sciences CMLS.

[143]  M. Neeman,et al.  In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. , 1999, Cancer research.

[144]  F. Mitjans,et al.  Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. , 1999, Cancer research.

[145]  W. Dalton,et al.  Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. , 1999, Blood.

[146]  E Biganzoli,et al.  Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[147]  D. Elder,et al.  Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. , 1998, The American journal of pathology.

[148]  E. Eisenhauer,et al.  Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[149]  S. A. Bush,et al.  Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  M V Knopp,et al.  Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[151]  K. Brindle,et al.  Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. , 1998, British Journal of Cancer.

[152]  T. A. Smith,et al.  FDG uptake, tumour characteristics and response to therapy: A review , 1998, Nuclear medicine communications.

[153]  N. van Bruggen,et al.  Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. , 1998, Cancer investigation.

[154]  M. Bednarski,et al.  Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. , 1998, Nature medicine.

[155]  P. Speight,et al.  Integrins and oral cancer. , 1997, Oral oncology.

[156]  J. Griffiths,et al.  Nuclear magnetic resonance spectroscopy of cancer. , 1997, The British journal of radiology.

[157]  R Simon,et al.  Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.

[158]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  J. Varner.  The role of vascular cell integrins αvß3 and αvß5 in angiogenesis , 1997 .

[160]  J. Varner.  The role of vascular cell integrins alpha v beta 3 and alpha v beta 5 in angiogenesis. , 1997, EXS.

[161]  Chandra L. Theesfeld,et al.  Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[162]  D. Cheresh,et al.  Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. , 1996, Important advances in oncology.

[163]  P. Price,et al.  Positron emission tomography: a new investigational area for cancer research. , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

[164]  D. Cheresh,et al.  Integrins, angiogenesis and vascular cell survival. , 1996, Chemistry & biology.

[165]  J E Mortimer,et al.  Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[166]  K. Aldape,et al.  Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. , 1995, Journal of cell science.

[167]  F. Mitjans,et al.  Alpha v beta 1 is a receptor for vitronectin and fibrinogen, and acts with alpha 5 beta 1 to mediate spreading on fibronectin. , 1995, Journal of cell science.

[168]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[169]  D. Cheresh,et al.  Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. , 1994, Cell.

[170]  K. Anderson,et al.  Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. , 1993, Blood.

[171]  M C Farach-Carson,et al.  Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. , 1993, The Journal of biological chemistry.

[172]  L. Pilarski,et al.  Expression of multiple β1 integrins on circulating monoclonal B cells in patients with multiple myeloma , 1993 .

[173]  P. Hees,et al.  A new perfluorocarbon for use in fluorine‐19 magnetic resonance imaging and spectroscopy , 1993, Magnetic resonance in medicine.

[174]  L. Pilarski,et al.  Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. , 1993, American journal of hematology.

[175]  R. Ott,et al.  c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[176]  K. Anderson,et al.  Characterization of adhesion molecules on human myeloma cell lines. , 1992, Blood.

[177]  T W Griffin,et al.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.

[178]  M. Horton,et al.  Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. , 1991, Experimental cell research.

[179]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.